Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Targeted Oncology
Published in: Targeted Oncology 6/2018

01-12-2018 | Meeting Report

Annual Congress of the European Society for Medical Oncology (ESMO): Munich, Germany, 19–23 October 2018

Author: Martin Chopra

Published in: Targeted Oncology | Issue 6/2018

Login to get access

Excerpt

More than 26,000 participants from 138 countries came together for the 2018 annual congress of the European Society for Medical Oncology (ESMO) in Munich. Over 2100 abstracts - representing nearly 116,000 patients who have taken part in clinical trials - were presented at the meeting, including 66 late-breaking abstracts, many of which were published on the day of their presentation in major medical journals. …
Literature
1.
Denkert C, Liedtke C, Tutt A, von Minckwitz G. Molecular alterations in triple-negative breast cancer—the road to new treatment strategies. Lancet. 2017;389:2430–42.CrossRef
2.
Robson M, Im SA, Senkus E, Xu B, Domcheck SM, Masuda N, et al. Olaparib for metastatic breast Cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523–33.CrossRef
3.
Litton JK, Tugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, et al. Talazoparib in patients with advanced breast Cancer and a germline BRCA mutation. N Engl J Med. 2018;379:753–63.CrossRef
4.
Clarke JM, George DJ, Lisi S, Salama AKS. Immune checkpoint blockade: the new frontier in Cancer treatment. Target Oncol. 2018;13(1):1–20.CrossRef
5.
6.
Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. IMpassion130: Results from a global, randomised, double-blind, phase 3 study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC). Ann Oncol. 2018;29(suppl_8) LBA1_PR.
7.
Vijayaraghavan S, Moulder S, Keyomarsi K, Layman RM. Inhibiting CDK in Cancer therapy: current evidence and future directions. Target Oncol. 2018;13:21–38.CrossRef
8.
Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17:425–39.CrossRef
9.
10.
11.
Cristofanilli M, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N. Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): Analyses from PALOMA-3. Ann Oncol. 2018;29(suppl_8) LBA2_PR.
12.
Araki K, Miyoshi Y. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer. Breast Cancer. 2018;25:392–401.CrossRef
13.
Baselga J, Dent SF, Cortés J, Im YH, Diéras V, Harbeck N, et al. Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER. J Clin Oncol. 2018;36(suppl_18) LBA1006.
14.
André F, Ciruelos EM, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): results of the Phase 3 SOLAR-1 trial. Ann Oncol. 2018;29(suppl_8) LBA3_PR.
15.
Kumbla RA, Figlin RA, Posadas EM. Recent advances in the medical treatment of recurrent or metastatic renal cell Cancer. Drugs. 2017;77:17–28.CrossRef
16.
Flippot R, Escudier B, Albiges L. Immune checkpoint inhibitors: toward new paradigms in renal cell carcinoma. Drugs. 2018;78:1443–57.CrossRef
17.
Motzer RJ, Penkov K, Haanen JBAG, Rini BI, Albiges L, Campbell MT, et al. JAVELIN Renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC). Ann Oncol. 2018;29(suppl_8) LBA6_PR.
18.
19.
O’Sullivan Coyne G, Chen AP, Meehan R, Doroshow JH. PARP inhibitors in reproductive system cancers: current use and developments. Drugs. 2017;77:113–30.CrossRef
20.
21.
Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, Firedlander M, et al. Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial. Ann Oncol. 2018;29(suppl_8) LBA7_PR.
22.
Moreira J, Tobias A, O’Brien MP, Agulnik M. Targeted therapy in head and neck Cancer: an update on current clinical developments in epidermal growth factor receptor-targeted therapy and immunotherapies. Drugs. 2017;77:843–57.CrossRef
23.
Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, De Castro G. KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Ann Oncol. 2018;29(suppl_8) LBA8_PR.
Metadata
Title
Annual Congress of the European Society for Medical Oncology (ESMO): Munich, Germany, 19–23 October 2018
Author
Martin Chopra
Publication date
01-12-2018
Publisher
Springer International Publishing
Published in
Targeted Oncology / Issue 6/2018
Print ISSN: 1776-2596
Electronic ISSN: 1776-260X
DOI
https://doi.org/10.1007/s11523-018-0608-8

Other articles of this Issue 6/2018

Targeted Oncology 6/2018 Go to the issue

Adis Drug Evaluation

Olaparib Tablet: A Review in Ovarian Cancer Maintenance Therapy

Original Research Article

PD-1 and PD-L1 Expression in Male Breast Cancer in Comparison with Female Breast Cancer

Original Research Article

Real-World Use and Outcomes of Olaparib: a Population-Based Cohort Study

Short Communication

Low Baseline Serum Sodium Concentration Is Associated with Poor Clinical Outcomes in Metastatic Non-Small Cell Lung Cancer Patients Treated with Immunotherapy

Acknowledgement to Referees

Acknowledgement to Referees

Review Article

Therapy of Advanced Prostate Cancer: Targeting the Androgen Receptor Axis in Earlier Lines of Treatment
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits